Biomx

Biomx EBITDA per Employee

The EBITDA per Employee of Biomx (PHGE) as of Oct 24, 2026 is -1.78 M USD. In the previous year, EBITDA per Employee was -1.88 M USD — a change of -4.98% (higher).

EBITDA per Employee

-1.78 MUSD

YoY

-4.98%

Last updated:

EBITDA per Employee of Biomx is 2025 -1.78 M USD. EBITDA per Employee of Biomx was 2024 -1.88 M USD. It decreases by -4.98% higher compared to the previous year.

The Biomx EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-51.50 USD
Jan 1, 2019
-1.09 M USD
Jan 1, 2020
-1.51 M USD
Jan 1, 2021
-1.65 M USD
Jan 1, 2022
-1.21 M USD
Jan 1, 2023
-1.35 M USD
Jan 1, 2024
-1.88 M USD
Jan 1, 2025
-1.78 M USD
The Biomx EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.78 MUSD-4.98%
-1.88 MUSD+39.53%
-1.35 MUSD+11.15%
-1.21 MUSD-26.72%
-1.65 MUSD+9.16%
-1.51 MUSD+38.25%
-1.09 MUSD+2.12 M%
-51.50USD-99.99%
-368,600.00USD+316.73%
-88,450.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomx Stock analysis

What does Biomx do? BiomX Ltd develops bacteriophage-based therapies targeting dysbiosis-related diseases, focusing on natural and engineered phage solutions. The company's pipeline includes BX001 for acne-prone skin, BX002 for IBD bacterial targets, and BX003 for Klebsiella pneumoniae strains. BiomX discovers and validates bacterial targets to customize phage compositions, aiming to treat conditions like inflammatory bowel disease, primary sclerosing cholangitis, and cancer through targeted bacterial destruction. The firm creates therapies for skin appearance issues and chronic diseases, with BX001 addressing acne, BX002 targeting IBD onset bacteria, and BX003 focusing on specific Klebsiella pneumoniae strains. BiomX's approach involves developing both natural and engineered phage cocktails tailored to bacterial targets, ensuring precise treatment for microbiome-related conditions without naming specific buyers or segments. BiomX Ltd's revenue model relies on the development and commercialization of its phage therapy pipeline. The company's products BX001, BX002, and BX003 are designed to treat specific bacterial-related conditions, with BX001 targeting skin appearance, BX002 for IBD, and BX003 for Klebsiella pneumoniae, all developed through customized phage compositions against validated bacterial targets. Biomx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomx stock

EBITDA per Employee of Biomx is -1.78 M USD in 2025.

EBITDA per Employee of Biomx changed from -1.88 M USD to -1.78 M USD, representing a -4.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Biomx since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Biomx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Biomx

All Key Metrics — Biomx